Medicina em FocoBook an appointment

PROCEDURES · HEALTH

Intravenous immunoglobulin: uses, how it is given, care and risks

Intravenous immunoglobulin is a treatment made from antibodies obtained from the plasma of thousands of healthy donors and given through a vein. It is used to replace antibodies in people with immunodeficiency and to modulate the immune system in autoimmune and inflammatory diseases, as prescribed by a neurologist or another specialist.

If your doctor mentioned intravenous immunoglobulin, it is natural to want to know how the infusion works and what to expect. We explain it step by step.

Schedule an evaluation

What it is

Human immunoglobulin is a product rich in a variety of antibodies. The medication is obtained by processing plasma and goes through steps to reduce the viral load. The intravenous form is given through a vein.

At replacement doses, it provides antibodies for people with immunodeficiency. It is also used to modulate the immune system in autoimmune and inflammatory diseases.

Purpose

  • Guillain-Barré syndrome in adults.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP).
  • Worsening (exacerbation) of myasthenia gravis; it is not recommended for stable disease.
  • Multifocal motor neuropathy.
  • Dermatomyositis.
  • Primary immunodeficiencies in which antibody production or function is impaired.

How it is done

The intravenous infusion can be given in a hospital, a hospital outpatient clinic, a doctor's office or at home, depending on each patient's circumstances.

For the first infusion, the rate starts low for the first 30 minutes and increases only if there is no reaction. Treatment may be divided over more than one day: in children with Guillain-Barré syndrome, for example, studies compared the standard dose given over two or five days.

Preparation

  • Blood tests before starting, which may include a complete blood count, kidney function tests (such as creatinine) and IgA levels.
  • Tell your doctor your age, any conditions you have (such as diabetes, high blood pressure, heart disease, stroke or thrombosis) and the medications you take, such as contraceptives and diuretics.
  • Hydration and a slower infusion are among the strategies used to reduce headaches caused by immunoglobulin.
  • In some cases, the doctor prescribes medications before the infusion to reduce reactions.
  • Your doctor will give you instructions specific to your case.

Recovery

Fatigue, headache, fever, chills and feeling unwell may occur and are usually mild and temporary.

In chronic inflammatory demyelinating polyneuropathy (CIDP), most patients need maintenance immunoglobulin treatment scheduled by the neurologist.

Risks and precautions

  • Headache, body aches, chills and fever during or shortly after the infusion, usually mild.
  • A severe allergic reaction (anaphylaxis), in which the infusion is stopped immediately and the team provides the necessary care.
  • Aseptic meningitis (inflammation of the meninges without infection), which may cause persistent headache, nausea, vomiting, sensitivity to light and fever.
  • Worsening kidney function, with a higher risk in older people and those with diabetes, kidney disease or dehydration.
  • Thrombosis, with a higher risk in older people, those who have had thrombosis, have atherosclerosis or use contraceptives.
  • Anemia caused by the destruction of red blood cells (hemolysis), which usually causes no symptoms and is detected on a blood test.

When to go to the emergency department after the procedure

  • A headache that does not go away, with fever, vomiting or sensitivity to light.
  • Shortness of breath or chest pain.
  • Suspected stroke, heart attack or thrombosis.
  • Low urine output or blood in the urine.
  • In these situations, go to the emergency department or call SAMU (Brazil's emergency medical service) at 192.

In an emergency, call 192 (SAMU, Brazil's emergency medical service) or go to the nearest emergency room.

Alternatives

Depending on the disease, other options are available. In severe Guillain-Barré syndrome, for example, plasmapheresis (plasma exchange) speeds recovery as much as immunoglobulin started within the first two weeks.

Immunoglobulin given under the skin is also available for antibody replacement. The choice depends on the diagnosis and is made by the doctor.

Frequently asked questions

Does an immunoglobulin infusion hurt?

During the infusion, you may have a mild headache, fever, chills or fatigue. These symptoms usually improve when the team slows the infusion rate.

How long does the injection session take?

Treatment may take more than one day: in studies involving children with Guillain-Barré syndrome, the standard dose was given over two or five days. The exact time depends on the case. The doctor will explain your treatment plan.

Will I need to be hospitalized?

Not always. The infusion can be given in a hospital, an outpatient clinic, a doctor's office or at home, depending on each patient's circumstances. For people at higher risk of a reaction, hospital monitoring is recommended for the first 24 hours after administration.

When can I return to work?

It depends on your condition and how you feel after the infusion. Talk to your doctor about your routine.

Can immunoglobulin transmit diseases?

Since modern controls and testing were introduced, there have been no reports of HIV or prion transmission through intravenous immunoglobulin.

Does my health plan cover intravenous immunoglobulin?

It depends on your health plan and the indication. Our team confirms coverage and what you need to submit.

Can an online consultation help?

An online consultation helps provide guidance, review test results and monitor your response to treatment. The neurological evaluation and infusion take place in person.

Where we see patients

Rua Frei Caneca, 1380, térreo (Edifício Crystal Tower), Consolação, São Paulo-SP, CEP 01307-000, Brasil

References

  1. Keller CW, Dalakas MC, Lünemann JD. Intravenous immunoglobulin use in neurology. Handb Clin Neurol. 2026.
  2. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013.
  3. Novaretti MC, Dinardo CL. Immunoglobulin: production, mechanisms of action and formulations. Rev Bras Hematol Hemoter. 2011.
  4. Tavee J, et al.; AANEM. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Muscle Nerve. 2023.
  5. Epland K, et al. A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. Allergy Asthma Clin Immunol. 2022.
  6. Guo Y, et al. Adverse Effects of Immunoglobulin Therapy. Front Immunol. 2018.
  7. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014.
  8. Keh R, et al. Routine blood monitoring in maintenance immunoglobulin treatment of inflammatory neuropathy: Is it clinically relevant? J Neurol Sci. 2020.
  9. Thornby KA, Henneman A, Brown DA. Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches. Ann Pharmacother. 2015.
  10. Kuitwaard K, et al. Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2017.
  11. Abolhassani H, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012.

This content is informational and does not replace a consultation.

Updated on